3 results
The main objectives are to understand how clinical markers and biomarkers previously identified in younger and older AD cohorts apply to the extreme elderly (90+ years old) and to identify novel biomarkers linked with resilience to developing…
The primary objective of this study is to demonstrate superiority in overall survival (OS) and comparable safety when eflornithineis added to lomustine compared to lomustine alone in patients with anaplastic astrocytoma (AA) that progress/recur…
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.